Pharmacoeconomic review report. Daclizumab (Zinbryta).
Daclizumab beta (Zinbryta, DAC) is a humanized, monoclonal antibody directed against the interleukin-2 receptor. DAC beta is indicated for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate,...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK535198/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario] :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
